The median time to progression - the primary end point - was significantly longer (9.8 months) among those on the combination, compared to those on docetaxel alone (7.0 months).
中位进展时间—首要观察终点—与所有单用多西他赛方案(7.0月)相比联合方案组的中位进展时间(9.8月)明显延长。
The median time to progression - the primary end point - was significantly longer (9.8 months) among those on the combination, compared to those on docetaxel alone (7.0 months).
中位进展时间—首要观察终点—与所有单用多西他赛方案(7.0月)相比联合方案组的中位进展时间(9.8月)明显延长。
应用推荐